Stereotactic radiosurgery is a valuable therapeutic modality in the management of large AVMs, and it has been adopted as an effective way to deliver a high dose of radiation in a highly conformal manner to maximally spare surrounding normal brain tissue and minimize the risk of radiation injury. Traditionally, the strategy for safely treating large AVMs at the University of California, San Francisco, has been a volume-staged SRS approach. This approach is used when the volume of the target is too large to safely deliver a single-fraction dose high enough to obliterate the target while maintaining the surrounding area treated by 12 Gy at an acceptable threshold. This is because the risk of post-SRS brain necrosis specific to AVM treatment has been found to correlate with the volume of normal brain surrounding the irradiated target area, which is exposed to 12 Gy. The technique involves first treating a portion of the target volume (typically the area of the nidus close to feeder veins) with the intended SRS dose, followed by treatments of remaining portions of the target volume in a sequential manner.

With the recent introduction of precision SRT technologies, such as the Gamma Knife Extend system, and LINAC-based modalities, such as the CyberKnife, hypofractionated SRT, in which a high dose is delivered to the target volume in 5 or fewer fractions, has been proposed. In particular, physician experiences with CyberKnife (Accuray) treatments that have been reported in the literature indicate encouraging preliminary results.
While a potential advantage to using hypofractionation is the reproducibility of targeting the same area without the risk of dynamic changes that may occur between treatment delivery sessions in a multistaged treatment, a key challenge is how to deliver a sufficiently high total dose to produce efficacy comparable to that of single-fraction SRS. In addition, while hypofractionated treatments theoretically allow better sparing of normal brain tissue and target dose delivery compared with volume-staged treatments, it is difficult to quantify a comparison between a traditional hypofractionated regimen and a volume-staged regimen.

The goal of our study was twofold: 1) to develop a volume-staged technique with accuracy comparable to that of existing SRT delivery; and 2) to develop data-driven hypofractionated treatment protocols by comparing biologically equivalent normal brain 12-Gy volumes from a hypofractionated treatment with those of a volume-staged Gamma Knife treatment.

Methods

Seven children with AVMs who had undergone volume-staged treatment with the Gamma Knife Perfexion (Elekta AB) at the University of California, San Francisco, were selected for the study. The mean target volume for these cases was 11.3 ± 2.2 cm³ (range 8.0–15.0 cm³). All patients underwent 2 volume-staged GKSS. The technical details of our volume-staging technique have been previously described. In brief, AVM target volumes are divided into 2 approximately equal portions, with each portion treated to a dose of 17 Gy or higher; the time interval between the 2 treatments is typically 6–9 months. To match the 2 volume-staged treatment plans, we developed a 3-dimensional image registration plus a landmark-based frame coordinate transformation procedure. The key goal of the procedure was to translate the Gamma Knife shot or isocenter coordinates from 1 frame system to another. Our procedure involved the following steps: 1) at both sessions, define the time-of-flight MR target image according to the treatment-day frame system; 2) at the second treatment session, coregister the MRI study obtained that day with the initial-frame MRI study obtained on the first treatment day via a voxel-based mutual information matching method; 3) identify the same landmark coordinates on the 2 imaging studies described in the first 2 steps; and 4) translate the radiation shot positions from the earlier treatment based on identified landmarks, which intrinsically specifies the 2 frame systems. Implementation of the fourth step is similar to that described in a previous study, except that the shot transformation matrix is determined via a nonlinear gradient search algorithm in an Excel spreadsheet with an embedded solver package (the spreadsheet is available and free from the corresponding author upon request).

For each volume-staged case, a corresponding Gamma Knife Extend plan was reconstructed. In addition, the imaging studies plus associated contour lines were exported via the DICOM-RT protocol using the Leksell GammaPlan image export tool (version 9.0, Elekta AB). The exported images and contour lines were then imported into the CyberKnife MultiPlan workstation (version 9.0, Accuray) for independent treatment planning. Since both Gamma Knife Extend system and CyberKnife treatments require a CT study for dose computation, a reference phantom CT study was used to merge with the MRI studies obtained in the pediatric patients for treatment plan optimization in a consistent manner. The CyberKnife treatment plans were optimized via the sequential inverse optimization routine. For all treatment plans, dose-volume constraints were imposed to produce a comparable dose to surrounding normal brain tissue while achieving the same target volume coverage as the corresponding Gamma Knife Extend system treatment plans.

Once a hypofractionated treatment plan had been developed, the hypofractionated total dose for each case was determined to produce an identical volume of normal brain receiving 12 Gy—the 12-Gy isodose volume minus the target volume, in biological equivalence to the corresponding volume-staged Gamma Knife treatment plan. For the purpose of illustration, suppose that a composite volume receiving 12 Gy in a volume-staged Gamma Knife treatment plan was found to equal 15.0 cm³, then when setting the target dose for an n-fraction SRT treatment, we would first adjust the prescribed dose value such that the plan produced exactly 15 cm³ of 12 Gy according to the biologically effective dose. In the context of the standard linear quadratic model, this means that 15 cm³ of the biologically effective dose equals 60 Gyβ, that is, 12 × (1 + 12/3) = 60 Gyβ, where α/β = 3 Gy is taken for the normal brain. Converting this into a hypofractionated n-fraction treatment, we can further compute a normal brain dose of d0 of any given n-fraction scheme as follows: d0(1 + dγ/3n) = 60 or d0 = 3/[Sqrt(80n + n2) − n].

Therefore, for an n-fraction SRT treatment, this means that the target dose can be adjusted so that the isodose volume of d0 would match the known volume receiving 12 Gy from the staged treatment (such as 15 cm³ in the example given previously). From Equation 1, we have dγ = 23.4 Gy if n = 5, dγ = 21.5 Gy if n = 4, dγ = 19.2 Gy if n = 3, and so forth.

Furthermore, the prescribed dose can be also be estimated based on an analytical model from our previous study, in which the prescribed target dose (d0) relating to a nearby peripheral isodose volume for a solitary target is given as follows: Vγ/Vγ = (dγ/d0)γ, where Vγ is the prescribed isodose volume, Vγ is the isodose volume corresponding to dγ, and γ is the power index approximately equal to −1.5 for radiosurgical deliveries.

Using the aforementioned example, suppose a target of Vγ = 11 cm³ and a volume receiving 12 Gy of Vγ = 15.0 cm³. Substituting dγ = 23.4 Gy for a 5-fraction treatment of Equation 1 results in Equation 2, one can then obtain an estimated target prescribed dose of d0 = 28.8 Gy in 5 fractions. This value was taken as the initial solution for individual treatment plans. For example, once such an estimated value is set for a case, the corresponding Vγ can be obtained. Depending on the differences between the computed Vγ and the desired Vγ value, the target dose can be then iteratively adjusted such that the resulting Vγ of the n-fraction treatment plan matches that determined from Equation 1.
Hypofractionation versus volume staging for treating large AVMs

Results

Our overall accuracy in the volume-stage frame matching for all the cases was a mean of 0.33 ± 0.09 mm with the maximum less than 0.5 mm. Such a result indicated that the whole-procedure accuracy of a volume-staged SRT agrees with the accuracy of the standard GKS to within 0.5 mm, a value approaching the mechanical accuracy of the latest Gamma Knife Perfexion system.14

The isodose distributions of a volume-staged Gamma Knife–treated AVM case are shown in Fig. 1A and B. The corresponding hypofractionated treatment plans are shown in Fig. 1C (CyberKnife) and Fig. 1D (Gamma Knife Extend system). The composite 12-Gy isodose volume (the isodose volume receiving 12 Gy, which is arrived at by summing the dose distributions of Fig. 1A and B) was 21.3 cm³ for the case. When matching the biologically effective 12-Gy volume for either SRT plan, a prescription dose of 29 Gy in 5 fractions was derived for the case.

The treatment plan summary for all case results is shown in Table 1. Because of the conformity and target coverage constraints imposed on the CyberKnife SRT and Gamma Knife Extend SRT plans for this study, the resulting 12-Gy isodose volumes agreed within 0.2 cm³ between the 2 systems and these values are shown in Table 1. For all cases, a reduction of 18.7% ± 7.3% in the equivalent single fractional dose was observed for the SRT plans to maintain the same 12-Gy isodose volumes as those of the volume-staged SRS treatments. Such a difference was statistically significant (p = 0.0014) based on the paired 2-tail Student t-test. The mean composite 12-Gy isodose volume for the staged treatments was 22.6 ± 5.6 cm³ versus 28.6 ± 6.9 cm³ for the SRTs.

The mean 12-Gy isodose volume to the ventricles adjacent the targets was 0.35 ± 0.48 cm³ for the staged treatments versus 0.63 ± 1.04 cm³ for the SRTs (p = 0.245). Subtracting the enclosed portion of the ventricle volumes and the target volumes from the total 12-Gy isodose volumes, as listed in Table 1, we obtained mean normal brain 12-Gy volumes of 22.2 ± 5.5 cm³ for the staged treatments and 27.9 ± 6.7 cm³ for the hypofractionated SRTs (p = 0.002).

The prescribed radiation dose guideline for SRTs, as derived from the studied cases, is shown in Fig. 2. The error bars on the plot represent 1 standard deviation value. From the results in Fig. 2, dose variations among individual cases tend to increase nonlinearly with increasing number of fractions. Based on the fitted curve, the most common 5-fractionation dose scheme for an SRT would be 27.3 Gy.

Discussion

We determined hypofractionation treatment schemes for large AVMs that would yield equivalent sparing of normal brain tissue to that of volume-staged GKS. The doses that our model derived are fundamentally based on the biologically equivalent 12-Gy single-fraction isodose volume as the predictor of treatment-related toxicity. The total doses plotted in Fig. 2 (for example, 27.0 Gy in 5 fractions and 24.0 Gy in 4 fractions) are in fact consistently lower than the current hypofractionated schemes reported in the literature. For example, Xiao et al.24 treated 20 large AVMs with 25–30 Gy in 5–6 Gy fractions and found an improvement in efficacy when using 30 Gy. Lindvall et al.15 examined 66 patients treated with 30–35 Gy in 5 fractions and found a higher rate of obliteration in patients treated with 35 Gy than in those treated with 30 Gy (88% vs 78%); however, the authors noted that all patients who experienced symptomatic necrosis belonged to the group treated with 35 Gy. Based on our calculations, 27 Gy may be the appropriate dose to strike a balance between efficacy and toxicity. However, more clinical data with hypofractionated treatments of large AVMs are required. These model calculations need to be further validated before general conclusions can be made about dose efficacy and the potential superiority of hypofractionated treatments over volume-staged treatments.

Our choice of the 12-Gy isodose volume as a dose sur-
 surrogate for normal brain tissue toxicity is well supported by the literature. In our previous studies we demonstrated similar physical peripheral isodose volume characteristics for a solitary target regardless of the isodose volume chosen (for example, 8-Gy, 10-Gy, or 12-Gy isodose volume) or the SRS treatment technology (Gamma Knife, CyberKnife or LINAC-based systems\(^1\)). Therefore, using a single peripheral isodose volume (such as the 12-Gy volume in our study) is sufficient as a surrogate for the overall 3-dimensional peripheral dose distribution inside normal brain tissue surrounding a radiosurgical target and, therefore, is not considered a limitation of the study.

In addition, the empirical parameter of \(a/b = 3\) Gy was adopted for the normal brain in our study. Such a value is well supported in the literature,\(^1\) and small variations in the \(a/b\) value, such as 10%, were found to introduce negligible changes in the curve shown in Fig. 2. Nonetheless, the application of the linear quadratic model for hypofractionated treatments has been a subject of debate, despite the fact that no other model has yet to be shown and accepted as superior.\(^2\)

One potential limitation of this study is the inability to account for the relatively long time period (6–9 months) between staged Gamma Knife treatments within the standard linear quadratic model. Our calculations have assumed that the normal brain sparing provided by such an extended time is identical to that provided by daily hypofractionated SRT delivery, but this is unlikely to be accurate. If, on the other hand for example, an extended time period was found to be more beneficial for sparing normal brain compared with daily-administered SRT delivery as expected, then the general conclusion of this study regarding the benefits of staged treatments would be further strengthened.

### Conclusions

The capability of hypofractionated SRTs for large AVMs to spare normal brain is equivalent to that of volume-staged SRS. However, the hypofractionated SRT dose necessary for this was found to be significantly lower than doses reported in current clinical practices. It is only with future clinical comparisons that we will know whether more patients have been subjected to higher rates of radiation necrosis than currently observed using volume-staged treatments.

### Disclosure

The authors acknowledge technical and equipment support provided by Elekta and Accuray for the study. Dr. McDermott shares a copyright with the University of California, San Francisco, for a medical device. Dr. Larson is a stockholder and member of the board of directors for American Shared Hospital Services.

Author contributions to the study and manuscript preparation include the following. Conception and design: Ma, Sneed, McDermott, Larson. Acquisition of data: Ma, Fogh, Gupta, Nakamura, Barani, Sneed, McDermott. Analysis and interpretation of data: Ma, Fogh, Gupta, Sahgal, McDermott, Larson. Drafting the article: Ma, Fogh, Sahgal, Larson. Critically revising the article: all authors. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Ma. Statistical analysis: Ma, Sahgal. Administrative/technical/material support: Ma, Gupta, Nakamura, Barani, Sneed, McDermott, Larson. Study supervision: Ma, Sneed, McDermott.
Hypofractionation versus volume staging for treating large AVMs

References

Address correspondence to: LiJun Ma, Ph.D., University of California, San Francisco, 505 Parnassus Avenue, Room L-08, San Francisco, California 94143; email: lijuna@radonc.ucsf.edu.

Accepted July 10, 2012.
This work was presented in part at the 16th International Meeting of the Leksell Gamma Knife Society, Sydney, Australia.
Please include this information when citing this paper: DOI: 10.3171/2012.7.GKS121023.